ArticleTherapeutic advances in medical oncology2025
Establishment and validation of a convenient and efficient screening tool for active pulmonary tuberculosis in lung cancer patients based on common parameters.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coexistent pulmonary tuberculosis and lung cancer (PTB-LC) is a rare type of disease with frequent under- and/or mis-diagnosis. Establishment of a reliable screening model for PTB-LC holds considerable medical and economic significance. Objectives: We aimed to develop an efficient and convenient tool to identify high-risk individuals for tuberculosis (TB) infection among LC patients based on commonly available parameters in clinical practice. Design: This study consisted of a primary retrospective patient cohort for model construction and verification, and a prospective patient cohort for prospective validation. Methods: Patients with active PTB-LC and LC diagnosed in Beijing Chest Hospital from 2018 to 2022 were collected and 1:1 matched according to time of admission and were classified into a training set ( Results: Through multivariable analysis, gender, pleural effusion, cavitation, monocyte count (MONO), and plasma adenosine deaminase (ADA) levels were identified as independent predictors of PTB-LC and included in model construction. LR, RF, SVM, DT, and NN were used to construct the screening or pre-diagnosis models. The RF demonstrated the best performance with an area under the curve of 0.966 in the training set, 0.817 in the testing set, and 0.805 in the prospective dataset. The accuracy, precision, recall, and F1 score of the RF model of the training set were 0.88, 0.87, 0.89, and 0.88, respectively, and these indicators of the testing set were 0.71, 0.75, 0.72, and 0.74, respectively, which were superior to those of other methods. The prospective cohort further validated the good performance of the screening model. We also established a nomogram with gender, pleural effusion, cavitation, MONO, and serum ADA in assessing high-risk patients of developing TB infection. Further TB-related diagnostic tests were recommended for these high-risk patients. Conclusion: The RF screening model constructed with gender, pleural effusion, cavitation, MONO, and ADA may help identify high-risk patients of PTB-LC from LC alone cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.